Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 1/2 7Phase 2 2Phase 3 1Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 143Myelodysplastic Syndromes 53Leukemia 24Leukemia, Myelomonocytic, Chronic 21Recurrence 12Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Peripheral 6Leukemia, Monocytic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Prostatic Neoplasms 3Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pancreatic Neoplasms 2

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × Azacitidine × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT04809181 2023-02-21

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
95 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡